215 related articles for article (PubMed ID: 32172199)
1. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.
Cohen R; Vernerey D; Bellera C; Meurisse A; Henriques J; Paoletti X; Rousseau B; Alberts S; Aparicio T; Boukovinas I; Gill S; Goldberg RM; Grothey A; Hamaguchi T; Iveson T; Kerr R; Labianca R; Lonardi S; Meyerhardt J; Paul J; Punt CJA; Saltz L; Saunders MP; Schmoll HJ; Shah M; Sobrero A; Souglakos I; Taieb J; Takashima A; Wagner AD; Ychou M; Bonnetain F; Gourgou S; Yoshino T; Yothers G; de Gramont A; Shi Q; André T;
Eur J Cancer; 2020 May; 130():63-71. PubMed ID: 32172199
[TBL] [Abstract][Full Text] [Related]
2. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Bellera CA; Penel N; Ouali M; Bonvalot S; Casali PG; Nielsen OS; Delannes M; Litière S; Bonnetain F; Dabakuyo TS; Benjamin RS; Blay JY; Bui BN; Collin F; Delaney TF; Duffaud F; Filleron T; Fiore M; Gelderblom H; George S; Grimer R; Grosclaude P; Gronchi A; Haas R; Hohenberger P; Issels R; Italiano A; Jooste V; Krarup-Hansen A; Le Péchoux C; Mussi C; Oberlin O; Patel S; Piperno-Neumann S; Raut C; Ray-Coquard I; Rutkowski P; Schuetze S; Sleijfer S; Stoeckle E; Van Glabbeke M; Woll P; Gourgou-Bourgade S; Mathoulin-Pélissier S
Ann Oncol; 2015 May; 26(5):865-872. PubMed ID: 25070543
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Gourgou-Bourgade S; Cameron D; Poortmans P; Asselain B; Azria D; Cardoso F; A'Hern R; Bliss J; Bogaerts J; Bonnefoi H; Brain E; Cardoso MJ; Chibaudel B; Coleman R; Cufer T; Dal Lago L; Dalenc F; De Azambuja E; Debled M; Delaloge S; Filleron T; Gligorov J; Gutowski M; Jacot W; Kirkove C; MacGrogan G; Michiels S; Negreiros I; Offersen BV; Penault Llorca F; Pruneri G; Roche H; Russell NS; Schmitt F; Servent V; Thürlimann B; Untch M; van der Hage JA; van Tienhoven G; Wildiers H; Yarnold J; Bonnetain F; Mathoulin-Pélissier S; Bellera C; Dabakuyo-Yonli TS
Ann Oncol; 2015 May; 26(5):873-879. PubMed ID: 25725046
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).
Bonnetain F; Bonsing B; Conroy T; Dousseau A; Glimelius B; Haustermans K; Lacaine F; Van Laethem JL; Aparicio T; Aust D; Bassi C; Berger V; Chamorey E; Chibaudel B; Dahan L; De Gramont A; Delpero JR; Dervenis C; Ducreux M; Gal J; Gerber E; Ghaneh P; Hammel P; Hendlisz A; Jooste V; Labianca R; Latouche A; Lutz M; Macarulla T; Malka D; Mauer M; Mitry E; Neoptolemos J; Pessaux P; Sauvanet A; Tabernero J; Taieb J; van Tienhoven G; Gourgou-Bourgade S; Bellera C; Mathoulin-Pélissier S; Collette L
Eur J Cancer; 2014 Nov; 50(17):2983-93. PubMed ID: 25256896
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.
Kramar A; Negrier S; Sylvester R; Joniau S; Mulders P; Powles T; Bex A; Bonnetain F; Bossi A; Bracarda S; Bukowski R; Catto J; Choueiri TK; Crabb S; Eisen T; El Demery M; Fitzpatrick J; Flamand V; Goebell PJ; Gravis G; Houédé N; Jacqmin D; Kaplan R; Malavaud B; Massard C; Melichar B; Mourey L; Nathan P; Pasquier D; Porta C; Pouessel D; Quinn D; Ravaud A; Rolland F; Schmidinger M; Tombal B; Tosi D; Vauleon E; Volpe A; Wolter P; Escudier B; Filleron T;
Ann Oncol; 2015 Dec; 26(12):2392-8. PubMed ID: 26371288
[TBL] [Abstract][Full Text] [Related]
6. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-Pélissier S; Bonnetain F
Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
[TBL] [Abstract][Full Text] [Related]
7. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.
Punt CJ; Buyse M; Köhne CH; Hohenberger P; Labianca R; Schmoll HJ; Påhlman L; Sobrero A; Douillard JY
J Natl Cancer Inst; 2007 Jul; 99(13):998-1003. PubMed ID: 17596575
[TBL] [Abstract][Full Text] [Related]
8. Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative.
Puijk RS; Ahmed M; Adam A; Arai Y; Arellano R; de Baère T; Bale R; Bellera C; Binkert CA; Brace CL; Breen DJ; Brountzos E; Callstrom MR; Carrafiello G; Chapiro J; de Cobelli F; Coupé VMH; Crocetti L; Denys A; Dupuy DE; Erinjeri JP; Filippiadis D; Gangi A; Gervais DA; Gillams AR; Greene T; Guiu B; Helmberger T; Iezzi R; Kang TW; Kelekis A; Kim HS; Kröncke T; Kwan S; Lee MW; Lee FT; Lee EW; Liang P; Lissenberg-Witte BI; Lu DS; Madoff DC; Mauri G; Meloni MF; Morgan R; Nadolski G; Narayanan G; Newton I; Nikolic B; Orsi F; Pereira PL; Pua U; Rhim H; Ricke J; Rilling W; Salem R; Scheffer HJ; Sofocleous CT; Solbiati LA; Solomon SB; Soulen MC; Sze D; Uberoi R; Vogl TJ; Wang DS; Wood BJ; Goldberg SN; Meijerink MR
Radiology; 2021 Dec; 301(3):533-540. PubMed ID: 34581627
[TBL] [Abstract][Full Text] [Related]
9. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Hudis CA; Barlow WE; Costantino JP; Gray RJ; Pritchard KI; Chapman JA; Sparano JA; Hunsberger S; Enos RA; Gelber RD; Zujewski JA
J Clin Oncol; 2007 May; 25(15):2127-32. PubMed ID: 17513820
[TBL] [Abstract][Full Text] [Related]
10. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.
Tolaney SM; Garrett-Mayer E; White J; Blinder VS; Foster JC; Amiri-Kordestani L; Hwang ES; Bliss JM; Rakovitch E; Perlmutter J; Spears PA; Frank E; Tung NM; Elias AD; Cameron D; Denduluri N; Best AF; DiLeo A; Baizer L; Butler LP; Schwartz E; Winer EP; Korde LA
J Clin Oncol; 2021 Aug; 39(24):2720-2731. PubMed ID: 34003702
[TBL] [Abstract][Full Text] [Related]
11. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
Le Tourneau C; Michiels S; Gan HK; Siu LL
J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
[TBL] [Abstract][Full Text] [Related]
12. Finding a consensus on time-to-event endpoints definitions in marginal zone lymphoma: A Delphi method.
Bommier C; Lambert J; Nowakowski G; Zucca E; Thieblemont C
Hematol Oncol; 2022 Dec; 40(5):1086-1089. PubMed ID: 35299287
[TBL] [Abstract][Full Text] [Related]
13. Alternative clinical end points in rectal cancer--are we getting closer?
Glynne-Jones R; Mawdsley S; Pearce T; Buyse M
Ann Oncol; 2006 Aug; 17(8):1239-48. PubMed ID: 16873440
[TBL] [Abstract][Full Text] [Related]
14. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
[TBL] [Abstract][Full Text] [Related]
15. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.
Shah MA; Renfro LA; Allegra CJ; André T; de Gramont A; Schmoll HJ; Haller DG; Alberts SR; Yothers G; Sargent DJ
J Clin Oncol; 2016 Mar; 34(8):843-53. PubMed ID: 26811529
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation.
Mercieca-Bebber RL; Perreca A; King M; Macann A; Whale K; Soldati S; Jacobs M; Efficace F
Eur J Cancer; 2016 Mar; 56():144-161. PubMed ID: 26851406
[TBL] [Abstract][Full Text] [Related]
17. The measurement and monitoring of surgical adverse events.
Bruce J; Russell EM; Mollison J; Krukowski ZH
Health Technol Assess; 2001; 5(22):1-194. PubMed ID: 11532239
[TBL] [Abstract][Full Text] [Related]
18. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.
Kamat AM; Sylvester RJ; Böhle A; Palou J; Lamm DL; Brausi M; Soloway M; Persad R; Buckley R; Colombel M; Witjes JA
J Clin Oncol; 2016 Jun; 34(16):1935-44. PubMed ID: 26811532
[TBL] [Abstract][Full Text] [Related]
19. Identification of consensus-based quality end points for colorectal surgery.
Manwaring ML; Ko CY; Fleshman JW; Beck DE; Schoetz DJ; Senagore AJ; Ricciardi R; Temple LK; Morris AM; Delaney CP
Dis Colon Rectum; 2012 Mar; 55(3):294-301. PubMed ID: 22469796
[TBL] [Abstract][Full Text] [Related]
20. Core outcome set for research studies evaluating treatments for twin-twin transfusion syndrome.
Perry H; Duffy JMN; Reed K; Baschat A; Deprest J; Hecher K; Lewi L; Lopriore E; Oepkes D; Khalil A;
Ultrasound Obstet Gynecol; 2019 Aug; 54(2):255-261. PubMed ID: 30520170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]